A prospective protocol increases oral anticoagulant prescription in patients with chronic, nonvalvular atrial fibrillation;Un protocolo prospectivo permite incrementar la utilización de anticoagulación oral en pacientes-con fibrilación auricular crónica no valvular

Revista Espanola de Cardiologia

Volumn 56, Issue 10, 2003, Pages 971-977

  Ruiz Ortiz, Martín ^a,b   Romo Peñas, Elías ^a   Franco Zapata, Manuel ^a   Mesa Rubio, Dolores ^a   Anguita Sánchez, Manuel ^a   López Granados, Amador ^a   Arizón del Prado, José M ^a   Vallés Belsué, Federico ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b NONE   (Spain)

Author keywords

Anticoagulants; Atrial fibrillation; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRESCRIPTION; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION;

EID: 0242438726     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052385     Document Type: Article

References (46)

1. Kannel WB, Abbot RD. Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation the Framingham study. N Engl J Med 1982;306:1018-22.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet 1987;1:526-9.
3. Sherman OG, Harr RG, Easton JD. The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986:43:68-70.
4. Petersen P, Madsen EB, Pedersen F, Gyldensyted C, Boysen G. Silent cerebral infarction in atrial fibrillation. Stroke 1987;18:1098-100.
5. Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke 1988;19:955-7.
6. Petersen P, Boysen G, Godtfresen J, Andersen DE, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of tromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175-9.
7. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Circulation 1991;84:527-39.
9. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 1991;18:349-55.
10. Ezekowitz MD, Bridgers SL, James KE. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1451-3.
11. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-62.
12. Atrial Fibrillation Investigators. The efficiency of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997;157:1237-40.
13. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin Versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994:343:687-91.
14. Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994;154:1443-8.
15. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-8.
16. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158: 1513-21.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation, analysis of pooled later from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
18. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995;25:452-9.
19. Mügge A, Kuhn H, Nikutta P. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with non-rheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994;23:599-607.
20. Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter. Determinants and relation to stroke. J Am Coll Cardiol 1996;27:1722-7.
21. Brand FN, Abott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-years follow-up in the Framingham Study. JAMA 1985;254:3449-53.
22. The Stroke Prevention in Atrial Fibrillation Investigators. Prevention of tromboembolism in atrial fibrillation: I y II: clinical y echocardiographics features of patients at risk. Ann Intern Med 1992;116:1-5.
23. Hylek FM, Singer DE. Risk factors for intracranial hemorrhage in patients taking warfarin. Ann Intern Med 1994;120:897-902.
24. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124:970-9.
25. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobsen A. Antithrombotic therapy in atrial fibrillation. 4th ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995; 108:3528-95.
26. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Prystowsky EN, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2001;38:1231-66.
27. Almendral J, Marín E, Medina O, Peinado R, Pérez L, Ruiz R, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. Rev Esp Cardiol 2001;54:307-67.
28. Heras M, Fernández A, Gómez JA, Iriarte JA, Lidón RM. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Rev Esp Cardiol 1999;52:801-20.
29. Vázquez Ruiz de Castroviejo E, Martín Rubio A, Pousibet Sanfeliu H, Lozano Cabezas C, Guzmán Herrera M, Tarabini Castellain A, et al. Utilización del tratamiento anticoagulante en los pacientes con fibrilación auricular no reumática. Rev Esp Cardiol 2000;53:200-4.
30. García Acuña JM, González Juanatey JR, Alegría Ezquerra E, González Maqueda I, Listerri JL. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol 2002;55:943-52.
31. Falco Ferrer V, Len Abad O, Iglesias Sáez D, Pérez Vega C, Reina D, Rosello J, et al. Análisis de los factores asociados a la indicación de tratamiento anticoagulante en la fibrilación auricular crónica. Estudio prospectivo de 170 pacientes ingresados en un servicio de medicina interna. Rev Clin Esp 2000;200:203-7.
32. Brotons C, Moral I, Anton JJ, Cobos M, Cucurull E, Gallego C, et al. Tratamiento preventivo de la fibrilación auricular no reumática: de la eficacia de los ensayos clínicos a la efectividad en la práctica clínica. Aten Primaria 1997;20:367-71.
33. Fuentes López T, Martín Aurioles E, Salgado Ordóñez F, Sánchez Silvestre A, Martos Crespo F, González Correa JA. Valoración del tratamiento antitrombótico en pacientes con fibrilación auricular cronica no valvular. Aten Primaria 1998;22:172-5.
34. Callejas JL, Ortego N, Díaz-Chamorro A, Troncoso E. Utilización de anticoagulación en pacientes con fibrilación auricular crónica no valvular. Med Clin (Barc) 1999;113:679.
35. Aloy-Duch A, Cuenca-Luque R, Rollán-Serrano E, Casanova-Sandoval JM. Utilización de fármacos antitrombóticos en pacientes con fibrilación auricular crónica en un área sanitaria comarcal. Med Clin (Barc) 1999;112:454-6.
36. Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract 2000;17:337-9.
37. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000;31: 1217-22.
38. Leckey RG, Aguilar E, Phillips SJ. Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol 2000;16:481-5.
39. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
40. Mead GE, Wardlaw JM, Lewis SC, McDowall M, Dennis MS. The influence of randomized trials on the use of anticoagulants for atrial fibrillation. Age Ageing 1999;28:441-6.
41. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, et al. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 1999;82:563-9.
42. Gaughan GL, Dolan C, Wilk-Rivard E, Geary G, Libbey R, Gilman MA, et al. Improving management of atrial fibrillation and anticoagulation in a community hospital. Jt Comm J Qual Improv 2000;26:18-28.
43. Freixa R, Blanch P, Ibernón M, Padró J, Delso J, Sobrepera JL, et al. Identificación de factores responsables de anticoagulación oral excesiva en pacientes ambulatorios con cardiopatía. Rev Esp Cardiol 2003;56:65-72.
44. Vázquez Ruiz de Castroviejo E, Martín Barranco MJ, Martín Rubio A, Fajardo Pineda A, Lozano Cabezas C, Guzmán Herrera M, et al. Cambios en el perfil clínico de los pacientes anticoagulados durante la década de los noventa. Rev Esp Cardiol 2002;55:55-60.
45. Cabrera Bueno F, Gómez Doblas JJ, Ruiz Ruiz M, Jiménez Navarro MF, Rodríguez Bailón I, Espinosa Caliani S, et al. Garantía y mejora de calidad en la atención al paciente con infarto agudo de miocardio. Implantación de un programa de calidad. Rev Esp Cardiol 2001;54:43-8.
46. Romo Peñas E, Ruiz Ortiz M, López Granados A, Mesa Rubio MD, Franco Zapata M, Anguita Sánchez M, et al. ¿Puede un protocolo prospectivo optimizar la indicación de anticoagulación en los pacientes con fibrilación auricular crónica no valvular? [abstract]. Rev Soc And Cardiol 2001;36:97-8.